Walvax Biotechnology Co., Ltd. (SHE:300142)
China · Delayed Price · Currency is CNY 12.28
+0.22 (1.82%)
At close: Mar 16, 2026
Walvax Biotechnology Revenue
Walvax Biotechnology had revenue of 564.60M CNY in the quarter ending September 30, 2025, a decrease of -20.25%. This brings the company's revenue in the last twelve months to 2.40B, down -22.54% year-over-year. In the year 2024, Walvax Biotechnology had annual revenue of 2.82B, down -31.41%.
Revenue (ttm)
2.40B
Revenue Growth
-22.54%
P/S Ratio
8.19
Revenue / Employee
1.00M
Employees
2,388
Market Cap
19.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.82B | -1.29B | -31.41% |
| Dec 31, 2023 | 4.11B | -972.67M | -19.12% |
| Jan 1, 2023 | 5.09B | 1.62B | 46.89% |
| Jan 1, 2022 | 3.46B | 523.81M | 17.82% |
| Dec 31, 2020 | 2.94B | 1.82B | 162.13% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Joincare Pharmaceutical Group Industry | 15.20B |
| Shandong Buchang Pharmaceuticals | 10.96B |
| China Resources Double-Crane Pharmaceutical | 10.95B |
| Apeloa Pharmaceutical Co.,Ltd | 10.50B |
| Tasly Pharmaceutical Group | 8.24B |
| Betta Pharmaceuticals | 3.26B |
| Tonghua Dongbao Pharmaceutical | 2.74B |
| Jilin Aodong Pharmaceutical Group | 2.34B |